D. Western Therapeutics Institute, Inc. (4576.T)
JPY 233.0
(14.22%)
JPY 233.0
(14.22%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -775.59 Million JPY | -202.54% |
| 2022 | -390.75 Million JPY | -123.85% |
| 2021 | -110.02 Million JPY | 54.28% |
| 2020 | -240.63 Million JPY | -249.0% |
| 2019 | 161.5 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -319.58 Million JPY | 11.03% |
| 2024 Q2 | -118.63 Million JPY | 41.86% |
| 2023 Q4 | -372.18 Million JPY | -87.25% |
| 2023 Q3 | -198.76 Million JPY | -30.2% |
| 2023 Q2 | -152.66 Million JPY | -51.59% |
| 2023 Q1 | -100.7 Million JPY | -137.59% |
| 2023 FY | - JPY | -202.54% |
| 2022 FY | - JPY | -123.85% |
| 2022 Q3 | -107.53 Million JPY | 0.0% |
| 2022 Q4 | -42.38 Million JPY | 60.58% |
| 2021 FY | - JPY | 54.28% |
| 2020 FY | - JPY | -249.0% |
| 2019 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 180.951% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | -58.89% |
| GNI Group Ltd. | 14.48 Billion JPY | 105.353% |
| Linical Co., Ltd. | 1.24 Billion JPY | 162.185% |
| Trans Genic Inc. | 240.95 Million JPY | 421.886% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 42.797% |
| Soiken Holdings Inc. | -583.2 Million JPY | -32.987% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | -28.603% |
| AnGes, Inc. | -8.86 Billion JPY | 91.246% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 39.666% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 89.518% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 705.424% |
| NanoCarrier Co., Ltd. | -863 Million JPY | 10.129% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | 28.961% |
| CanBas Co., Ltd. | 53.65 Million JPY | 1545.623% |
| RaQualia Pharma Inc. | -111.8 Million JPY | -593.725% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 35.993% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 43.831% |
| PeptiDream Inc. | 7.37 Billion JPY | 110.515% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 59.808% |
| Ribomic Inc. | -1.01 Billion JPY | 23.4% |
| SanBio Company Limited | -4.52 Billion JPY | 82.86% |
| Healios K.K. | -3 Billion JPY | 74.207% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 33.471% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 44.325% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 44.68% |
| StemRIM | -2.03 Billion JPY | 61.831% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 159.367% |
| FunPep Company Limited | -952 Million JPY | 18.53% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 12.734% |
| Stella Pharma Corporation | -723.85 Million JPY | -7.147% |
| TMS Co., Ltd. | -937 Million JPY | 17.226% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -0.026% |
| Cuorips Inc. | -518 Million JPY | -49.728% |
| K Pharma,Inc. | 366.05 Million JPY | 311.877% |
| Takara Bio Inc. | 8.02 Billion JPY | 109.666% |
| ReproCELL Incorporated | 8.24 Million JPY | 9506.804% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 981.975% |
| StemCell Institute Inc. | 534.35 Million JPY | 245.146% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 416.808% |
| CellSeed Inc. | -836.51 Million JPY | 7.283% |